The global orthobiologics market was valued at $5030 million in 2020 and is projected to reach $7960 million by 2027, registering a CAGR of 4.6% from 2021 to 2027. Orthobiologics are biological substances that are used to help injuries to heal more quickly. Orthobiologics are used to improve the healing of injured muscles, fractures, tendons, and ligaments. Orthobiologics are made from substances that occur naturally in the body. When they are used in more amounts, they may help to increase the healing process. When a tissue is injured bleeding occurs, after bleeding matrix, stem cells and growth factors play an important role in tissue healing and they are natural orthobiologics in human body. Matrix serves as building blocks that help to fill tissue gaps. Growth factors act on stem cells to cause the repair of the injured tissue. The rise in the global geriatric population, which is more susceptible to diseases like osteoarthritis and others, is fueling the expansion of the orthobiologics market. Other factors projected to drive market growth include increased awareness of orthobiologics and increased demand for improved therapy. Furthermore, during the projected period, strong development potential in developing countries and an increase in demand for sophisticated treatment are expected to generate new possibilities for market competitors. However, the market’s expansion is hampered by the greater cost of orthobiologics and the lengthy approval process.Because of the rising prevalence of OA, a better understanding of the disease pathophysiology, improved early detection, disease prevention strategies, and early management are all urgently needed. Orthobiologics may be one such treatment option for OA.